Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Sunitinib. Found 9 abstracts

Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2020 Apr;203(4):684-9.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27.
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DY, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer. 2018 Oct 22;6(1):109.   PMCID: PMC6196426
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DY, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer. 2018 Oct 22;6(1):109.   PMCID: PMC6196426
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
Abbosh PH, McConkey DJ, Plimack ER. Targeting Signaling Transduction Pathways in Bladder Cancer. Current oncology reports. 2015 Dec;17(12):58.
Kim JY, Hwang J, Lee SH, Lee HJ, Jelinek J, Jeong H, Lim JS, Kim JM, Song KS, Kim BH, Lee S, Kim J. Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells. Clinical epigenetics. 2015 Jan;7(1):99.   PMCID: PMC4572656
Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 2011 Sep;68(3):703-12.   PMCID: not NIH funded
Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen JH, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer. 2011 Dec;47(18):2706-14.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Sunitinib

Sunitinib Male Female Renal Cell Carcinoma Middle Aged Kidney Neoplasms Pazopanib Antineoplastic Agents Aged therapeutic use drug therapy Adult Tyrosine kinase inhibitor mortality carcinoma Axitinib Antineoplastic Combined Chemotherapy Protocols Sorafenib therapy adverse effects Adjuvant Chemotherapy Immune checkpoint inhibitor administration & dosage pathology Nivolumab Chemotherapy Metastatic renal cell carcinoma Disease-Free Survival Antiangiogenic interferon-alpha growth-factor chemotherapy Follow-Up Studies Vascular endothelial growth factor Pyrroles Randomized Controlled Trials as Topic Drug Administration Schedule Prospective Studies analogs & derivatives Treatment Outcome Progression-Free Survival Erbb3 methods Erbb2 survival local Bevacizumab Oral Administration Phase III Clinical Trials as Topic Double-Blind Method Sulfonamides prognosis Anti-vascular endothelial growth factor antibody renal cell Solid tumor Pyrimidines Prognosis Niacinamide 2008 iorean eg-v26-p2008 Phase I Copy number abnormality bevacizumab mTOR diagnostic imaging iii trial experience metabolism Dovitinib Mutation classification Nephrectomy Antiangiogenesis Intention to Treat Analysis Cetuximab metastatic breast-cancer epidemiology Egfr Monoclonal Antibodies-Humanized Vascular endothelial growth factor receptor pharmacology Single-Blind Method human liver-microsomes Renal cancer surgery 80 and over Aged Bladder cancer Phenylurea Compounds Fgfr3 NSCLC ABT-869 double-blind Erlotinib Local Neoplasm Recurrence Programmed Cell Death 1 Receptor Angiogenesis inhibitors tyrosine kinase inhibitor Kidney Neoplasm Staging Pten Survival Rate antagonists & inhibitors VEGFR Multicenter Studies as Topic Pik3ca Intravenous Administration Risk Assessment cell lung-cancer Everolimus Renal cell carcinoma Indoles neoplasm recurrence
Last updated on Monday, July 06, 2020